Overview

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is randomized, multicentre study aimed to compare a standard maintenance therapy with Interferon-Dexamethasone with an experimental therapy based on Thalidomide-Dexamethasone in patients with multiple myeloma who responded to ThaDD induction therapy
Phase:
Phase 3
Details
Lead Sponsor:
Università Politecnica delle Marche
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Interferon-alpha
Interferons
Liposomal doxorubicin
Thalidomide